12,500 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by ING Groep NV

ING Groep NV bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 12,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,044,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Handelsbanken Fonder AB grew its position in shares of Intra-Cellular Therapies by 3.0% during the 4th quarter. Handelsbanken Fonder AB now owns 27,100 shares of the biopharmaceutical company’s stock valued at $2,263,000 after buying an additional 800 shares during the last quarter. Ieq Capital LLC grew its holdings in shares of Intra-Cellular Therapies by 469.4% during the fourth quarter. Ieq Capital LLC now owns 32,398 shares of the biopharmaceutical company’s stock valued at $2,706,000 after purchasing an additional 26,708 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after purchasing an additional 402,186 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Intra-Cellular Therapies by 7.2% during the 4th quarter. New York State Common Retirement Fund now owns 76,563 shares of the biopharmaceutical company’s stock worth $6,395,000 after purchasing an additional 5,162 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on ITCI shares. JPMorgan Chase & Co. upped their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Finally, StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Monday. They set a “hold” rating on the stock. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 2.60% of the stock is owned by company insiders.

Intra-Cellular Therapies Price Performance

ITCI opened at $128.60 on Monday. The business has a 50 day moving average price of $110.27 and a two-hundred day moving average price of $89.84. The company has a market capitalization of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 1-year low of $62.78 and a 1-year high of $128.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.